TWO · 4105.TWO
TTY Biopharm Company Limited
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
Loading market information…
TWO · 1799.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Easywell Biomedicals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Easywell Biomedicals, Inc.’s forward annual dividend is NT$1.77 per share, paid annual. The forward yield is 6.84% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Easywell Biomedicals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; TLX-011 for treatment of inflammatory lesions of rosacea; TLX-015 a prevention and treatment medicine for postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, an anti-inflammatory medicine; TLX-47, an anti-inflammatory drug; and TLX-024, an anticonvulsant. It also develops TWB-201 for Parkinson patch; TLX-501, a urinary medicine; and TLX-502, a pneumonia medicine. In addition, the company provides thermometers, medical devices, and health food and products. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:05 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$14.05-NT$0.35 (-2.43%)
Microbio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 38.38% below the high.
NT$30.55-NT$0.20 (-0.65%)
Sinphar Pharmaceutical Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
NT$23.30-NT$0.20 (-0.85%)
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
NT$45.95-NT$0.55 (-1.18%)
Formosa Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.82% below the high.
NT$43.50-NT$0.30 (-0.68%)
Orient EuroPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$76.80+NT$0.30 (+0.39%)
SYN-TECH Chem. & Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.42% below the high.
NT$22.90-NT$0.10 (-0.43%)
Johnson Chemical Pharmaceutical Works Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.1% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
